Found: 26
Select item for more details and to access through your institution.
Stéphane Bancel.
- Published in:
- Nature Reviews Drug Discovery, 2015, v. 14, n. 6, p. 378, doi. 10.1038/nrd4646
- Publication type:
- Article
An acute, ulcerative, sarcoidal tattoo reaction following SARS-CoV-2 mRNA-1273 vaccination.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Moderna's $450-million venture round.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 2, p. 119, doi. 10.1038/nbt0215-119d
- Publication type:
- Article
Tramadol versus codéine.
- Published in:
- Médecine, 2022, v. 18, n. 1, p. 13, doi. 10.1684/med.2022.729
- By:
- Publication type:
- Article
Stevens–Johnson syndrome precipitated by Moderna Inc. COVID‐19 vaccine: a case‐based review of literature comparing vaccine and drug‐induced Stevens–Johnson syndrome/toxic epidermal necrolysis.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 8, p. 923, doi. 10.1111/ijd.16222
- By:
- Publication type:
- Article
COVID-19 Vaccine-induced Skin Rash: A Case Study.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Moderna, Pfizer Vaccines Work Better in Men: New Research.
- Published in:
- Indian Practitioner, 2021, v. 74, n. 5, p. 46
- Publication type:
- Article
Baby Born to Partially Vaccinated Mother Has Covid Antibodies.
- Published in:
- Indian Practitioner, 2021, v. 74, n. 3, p. 51
- Publication type:
- Article
THE GORDON WILSON LECTURE: RAPID COVID-19 VACCINE DEVELOPMENT AND THE FUTURE OF VACCINOLOGY.
- Published in:
- Transactions of the American Clinical & Climatological Association, 2023, v. 133, p. 103
- By:
- Publication type:
- Article
market solutions.
- Published in:
- 2007
- Publication type:
- Product Review
Moderna's mRNA Vaccine for Seasonal Flu Enters Clinical Trials.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines.
- Published in:
- JAMA: Journal of the American Medical Association, 2021, v. 325, n. 9, p. 898, doi. 10.1001/jama.2021.1375
- By:
- Publication type:
- Article
Early clinical trial data and real‐world assessment of COVID‐19 vaccines: Insights from the Society of Infectious Diseases Pharmacists.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 10, p. 837, doi. 10.1002/phar.2622
- By:
- Publication type:
- Article
Business: The billion-dollar biotech.
- Published in:
- Nature, 2015, v. 522, n. 7554, p. 26, doi. 10.1038/522026a
- By:
- Publication type:
- Article
In Pflzer We Trust?
- Published in:
- Social Policy, 2020, v. 50, n. 4, p. 86
- By:
- Publication type:
- Article
COVID‑19 antibody production by vaccination in chemotherapy with CD20 antibody for B‑cell lymphoma.
- Published in:
- Molecular & Clinical Oncology, 2023, v. 19, n. 6, p. N.PAG, doi. 10.3892/mco.2023.2692
- By:
- Publication type:
- Article
Self-Reported Reactogenicity After Different COVID-19 Vaccination Regimens: An Analysis of Registry-Based Data.
- Published in:
- Deutsches Ärzteblatt International, 2022, v. 119, n. 43, p. 727, doi. 10.3238/arztebl.m2022.0298
- By:
- Publication type:
- Article
Big Pharma and Omicron.
- Published in:
- CounterPunch, 2021, p. 1
- By:
- Publication type:
- Article
Why Moderna Refuses to Share Rights to the COVID-19 Vaccine With the Government That Paid for Its Development.
- Published in:
- CounterPunch, 2021, p. 1
- By:
- Publication type:
- Article
Why Are Moderna's Billionaires Airbrushing Scientists Out of the Vaccine Patent Picture?
- Published in:
- CounterPunch, 2021, p. 1
- By:
- Publication type:
- Article
Phase 3 Trial of Combination Flu/SARS-CoV-2 Vaccine Meets All Primary Endpoints: Moderna.
- Published in:
- Patient Care (Online), 2024, p. 3
- By:
- Publication type:
- Article
FDA Approves Moderna's mRESVIA, First mRNA Vaccine Against RSV, for Adults Aged ≥60 Years.
- Published in:
- Patient Care (Online), 2024, p. 3
- Publication type:
- Article
Moderna Next-Gen mRNA COVID-19 Vaccine Meets Primary Endpoints in NextCOVE Phase 3 Trial.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
Moderna mRNA RSV Vaccine for Adults Returns Positive Phase 3 Results.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article